Company News
Merck Shares Drop 3.7% on Kidney Trial
Merck & Co. shares fell 3.7% after Phase 3 LITESPARK‑012 trial in advanced renal cell carcinoma failed to meet primary endpoints.
The trial enrolled 1,688 patients and compared two experimental combos
